Prophylactic mastectomy for the prevention of breast cancer

Authors:
  • NCNora E Carbine
    Nora E Carbine
  • JWJudi Wallace
    Judi Wallace
  • JEJeanette Ezzo
    Jeanette Ezzo
  • KDKay Dickersin
    Kay Dickersin

Abstract
Recent progress in understanding the genetic basis of breast cancer has increased interest in prophylactic mastectomy as a method of preventing breast cancer. Primary objective: To determine whether prophylactic mastectomy reduces death from any cause in women who have never had breast cancer and in women who have a history of breast cancer in one breast. Secondary objectives: To examine the effect of prophylactic mastectomy on other endpoints including breast cancer incidence, breast cancer mortality, disease‐free survival, physical morbidity, and psychosocial outcomes. Electronic searches were performed in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Cancerlit, and the Science Citation Index. Inclusion criteria were studies in English of any design type. Participants included women at risk for breast cancer in at least one breast. Interventions included all types of mastectomy performed for the purpose of preventing breast cancer. Data for each study were summarized descriptively; quantitative meta‐analysis was not feasible due to heterogeneity of study designs and insufficient reporting. Data were analyzed separately for bilateral prophylactic mastectomy (BPM) and contralateral prophylactic mastectomy (CPM). All included studies were observational studies with some methodological limitations; no randomized trials were found. All studies reporting on incidence of breast cancer and disease‐specific mortality reported reductions after BPM including those with BRCA1 and 2 mutations. Nine studies assessed psychosocial measures; most reported high levels of satisfaction with the decision to have prophylactic mastectomy (PM) but more variable satisfaction with cosmetic results. Worry over breast cancer was significantly reduced after BPM when compared both to baseline worry levels and to the groups who opted for surveillance rather than BPM. For CPM, studies consistently reported reductions in contralateral incidence of breast cancer but were inconsistent about improvements in disease‐specific survival. Only one study attempted to control for multiple differences between intervention groups; this study showed no overall survival advantage for CPM at 15 years. Two case series were exclusively focused on adverse events from prophylactic mastectomy with reconstruction; both reported rates of unanticipated re‐operations from 30% to 49%. While published observational studies demonstrated that BPM was effective in reducing both the incidence of, and death from, breast cancer, more rigorous prospective studies (ideally randomized trials) are needed. BPM should be considered only among those at very high risk of disease. There is insufficient evidence that CPM improves survival.

This publication has 138 references indexed in Scilit: